MedTrace Logo

Morphine Slow-release Capsules in Substitution Therapy

NCT01079117 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 276

Last updated 2014-03-28

No results posted yet for this study

Summary

To compare the effectiveness of slow release oral morphine treatment in patients that previously have been treated with methadone

Conditions

  • Opiate Dependent

Interventions

DRUG

Sevre-Long™

The subjects will be randomised to either 10 weeks of treatment with methadone or SROM. After an adjustment phase of one week they first will be medicated for 10 weeks with the treatment to which they have been randomised. The cross-over, in which all subjects change to their opposite treatment, will serve for an additional adjustment phase of one week. After the second and new adjustment phase they are treated for 10 weeks with the newly adjusted medication. After the end of week 22 all participants continue with or switch back to SROM for another 6 month (week 23 to 47).

DRUG

Slow release oral morphine

DRUG

Methadone

Sponsors & Collaborators

  • Mundipharma Medical Company

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2011-06-30
Completion
2011-06-30

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01079117 on ClinicalTrials.gov